Program
BT02
A development code.
Its studies are mostly in Hematologic Neoplasms · Carcinoma, Non-Small-Cell Lung · Melanoma, led by Biotroy Therapeutics.
Furthest: phase 2, since Jul 30, 20253 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biotroy Therapeutics | 33 open or running | phase 2since Jul 30, 2025 | Jul 16, 2025 | Mar 2027phase 1 · NCT07110363 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 16, 2025First studies: 2 phase 1 studiesFirst studyNCT07107178, NCT07110363
- Jul 30, 2025Phase 2 study in RecurrenceNCT07107204 · 116 planned
Ahead
- Mar 2027Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07110363
- May 2027Primary completion: phase 1 study in Advanced MelanomaNCT07107178
- Jan 2028Primary completion: phase 2 study in RecurrenceNCT07107204
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07107204Recurrence | 2 | Not yet recruiting | Jan 2028 | 116 |
| NCT07110363Carcinoma, Non-Small-Cell Lung | 1 | Not yet recruiting | Mar 2027 | 58 |
| NCT07107178Advanced Melanoma | 1 | Not yet recruiting | May 2027 | 58 |
How it is read
Names in the registry
- “BT02”, 3 entries
Codes read as this program: BT02.
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
- Melanoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.